Immutep (IMMP) told investors its lung cancer treatment could become a new standard of care. Executives pointed to strong safety data, impressive survival results, and rapid enrollment in its Phase Three TACTI-zero zero four trial. But the complaint alleges the company was aware of, or reckless in disregarding, internal information suggesting the trial faced a materially increased risk of failing its primary endpoints.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immutep Limited has been sued over allegations that it misled investors about the progress and prospects of its TACTI-004 Phase III lung cancer trial. The complaint says the truth emerged on March 13, 2026, when the company disclosed that an independent monitoring committee recommended stopping the study for futility, after which Immutep’s ADRs fell about 83% in one day, from $2.76 to $0.48.
The proposed class period runs from March 24, 2025, through March 12, 2026. Investors who bought Immutep ADRs during that period may want to review the complaint and assess their rights.
Company Background
Immutep is described in the complaint as an Australian-based biotechnology company focused on LAG-3-related immunotherapies for cancer and autoimmune diseases. The filing says its product pipeline included TACTI-004, a Phase III clinical trial for first-line non-small cell lung cancer.
The lawsuit centers on the company’s public updates about TACTI-004 and related prior studies. According to the complaint, Immutep repeatedly cited earlier efficacy and safety readouts from TACTI-002 and INSIGHT-003 to support the Phase III program.
Core Allegations
The complaint says the case concerns whether Immutep overstated the viability of TACTI-004 while concealing adverse information about the trial’s efficacy and safety prospects. It alleges that the company described the study as on track, building momentum, and supported by positive prior data, even though internal information allegedly showed materially increased risk that the trial would fail its primary endpoints.
Plaintiff claims those statements were false or misleading because they painted a more positive picture of the Phase III program than the company knew was justified. The overarching theme is that investors were encouraged to rely on upbeat trial updates while key clinical risks were allegedly withheld.
Investors following the case may want to track how the allegations develop as the complaint moves forward.
Management Statements
The complaint quotes CEO Marc Voigt as saying on March 24, 2025, that dosing the first patient was one of the company’s most significant milestones and that TACTI-004 could deliver a new standard of care and a clinically meaningful survival benefit. It also quotes Chief Scientific Officer Frédéric Triebel as saying the combination had been demonstrated across multiple clinical trials and had an excellent safety profile with strong efficacy.
Later company updates repeated similar themes. On October 9, 2025, Voigt said the trial remained on track for key milestones, including futility analysis in early 2026, and on December 16, 2025, he described the program as showing strong operational progress and robust recruitment.
The complaint also cites a January 29, 2026, update saying the trial’s futility analysis remained on track for the first quarter of 2026. On February 6, 2026, Voigt again highlighted the excellent pace of enrollment and said the company looked forward to delivering upcoming milestones.
Corrective Disclosures
On March 13, 2026, Immutep announced that the independent data monitoring committee for TACTI-004 recommended discontinuing the trial after a planned interim futility analysis. The company also said the committee recommended stopping the study for futility based on its review of available safety and efficacy data.
The complaint says the market reacted immediately. Immutep’s ADRs closed at $2.76 on March 12, 2026, and fell to $0.48 on March 13, 2026, a decline of about 83%.
Why This Matters
For investors, the case is about whether the company’s repeated optimism about TACTI-004 masked a materially different clinical picture. The complaint ties the alleged misstatements to investor losses, alleging that the stock price had been artificially inflated until the March 13 disclosure.
Anyone who bought Immutep ADRs during the class period could be affected if the allegations in the complaint are proven. The lawsuit also points to analyst reactions after the disclosure as evidence that the market viewed the trial halt as a major negative development.
Legal Claims
The complaint asserts claims under Section 10(b) of the Exchange Act, Rule 10b-5, and Section 20(a) against the individual defendants. In plain terms, the plaintiff claims the defendants made false or misleading statements, or omitted material information, about the status and prospects of the TACTI-004 trial.
The filing says those statements were made while the company allegedly had access to internal clinical data suggesting the study faced a materially higher risk of failure. It also alleges the individual executives controlled the company’s disclosures and are therefore liable as controlling persons.
Investors who purchased or otherwise acquired Immutep ADRs during the class period may want to learn more about their rights.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has extensive expertise and a team of over 70 employees to serve our clients. Attorney advertising. Prior results do not guarantee similar outcomes.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article. Past results do not guarantee similar outcomes.